Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX -10.00% EV-to-OCF is -2.30 as of Aug. 28, 2026. The stock has 4 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Imagion Biosystems ranks better than 64.15% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Imagion Biosystems's Enterprise Value is A$9.34 Mil.
Imagion Biosystems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was A$-4.05 Mil. Therefore, Imagion Biosystems's EV-to-OCF for today is -2.30.
The historical rank and industry rank for Imagion Biosystems's EV-to-OCF or its related term are showing as below:
ASX:IBX'
s EV-to-OCF Range Over the Past 10 Years
Min: -29.61 Med: -1.1 Max: 1.19
Current: -2.5
During the past 9 years, the highest EV-to-OCF of Imagion Biosystems was 1.19. The lowest was -29.61. And the median was -1.10.
ASX:IBX's EV-to-OCF is ranked better than 64.15% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.965
vs ASX:IBX: -2.50
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Imagion Biosystems's PE Ratio (TTM) for today is calculated as:
Imagion Biosystems's share price for today is A$0.009.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was A$-0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Imagion Biosystems EV-to-OCF Related Terms
Imagion Biosystems EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Imagion Biosystems's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's EV-to-OCF falls into.
Imagion Biosystems's current Enterprise Value is A$9.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was A$-4.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (ASX:IBX) has a EV-to-OCF of -2.30 as of Aug. 28, 2026. According to the industry distribution chart, Imagion Biosystems ranks #76 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 35.8%.
Is Imagion Biosystems' EV-to-OCF too high?
Imagion Biosystems' current EV-to-OCF is -2.30. Based on the distribution chart, Imagion Biosystems ranks #76 out of 212 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Imagion Biosystems' EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #76 out of 212 companies for EV-to-OCF. This puts Imagion Biosystems in the upper half of its industry. The industry median EV-to-OCF is 5.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 5.97, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 5.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current EV-to-OCF is -2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 99.2% below its estimated fair value. The current EV-to-OCF is -2.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current EV-to-OCF is -2.30 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
